These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24290925)

  • 1. Optimal drug regimens in cancer chemotherapy: a multi-objective approach.
    Batmani Y; Khaloozadeh H
    Comput Biol Med; 2013 Dec; 43(12):2089-95. PubMed ID: 24290925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.
    Iliadis A; Barbolosi D
    Comput Biomed Res; 2000 Jun; 33(3):211-26. PubMed ID: 10860586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dosage regimen optimization in cancer chemotherapy using a mathematical model].
    Barbolosi D; Freyer G; Ciccolini J; Iliadis A
    Bull Cancer; 2003 Feb; 90(2):167-75. PubMed ID: 12660135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model.
    Chen JH; Kuo YH; Luh HP
    Math Biosci; 2013 Oct; 245(2):282-98. PubMed ID: 23927854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function.
    Engelhart M; Lebiedz D; Sager S
    Math Biosci; 2011 Jan; 229(1):123-34. PubMed ID: 21129386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
    Clairambault J
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal control oriented to therapy for a free-boundary tumor growth model.
    Calzada MC; Fernández-Cara E; Marín M
    J Theor Biol; 2013 May; 325():1-11. PubMed ID: 23485361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Algorithms for scheduling of chemotherapy plans.
    Sevinc S; Sanli UA; Goker E
    Comput Biol Med; 2013 Dec; 43(12):2103-9. PubMed ID: 24290927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined effect of optimal control and swarm intelligence on optimization of cancer chemotherapy.
    Shindi O; Kanesan J; Kendall G; Ramanathan A
    Comput Methods Programs Biomed; 2020 Jun; 189():105327. PubMed ID: 31978808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new optimization based approach to experimental combination chemotherapy.
    Pereira FL; Pedreira CE; de Sousa JB
    Front Med Biol Eng; 1995; 6(4):257-68. PubMed ID: 7612501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical modeling of tumor growth, drug-resistance, toxicity, and optimal therapy design.
    Hadjiandreou MM; Mitsis GD
    IEEE Trans Biomed Eng; 2014 Feb; 61(2):415-25. PubMed ID: 24021634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal chemotherapy regimens: influence of tumours on normal cells and several toxicity constraints.
    Matveev AS; Savkin AV
    IMA J Math Appl Med Biol; 2001 Mar; 18(1):25-40. PubMed ID: 11339336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mathematical model of cancer chemotherapy with an optimal selection of parameters.
    Martin RB; Fisher ME; Minchin RF; Teo KL
    Math Biosci; 1990 May; 99(2):205-30. PubMed ID: 2134520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
    Ledzewicz U; Schättler H
    Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of an optimal control strategy for drug administration in tumor treatment using multi-objective optimization differential evolution.
    Lobato FS; Machado VS; Steffen V
    Comput Methods Programs Biomed; 2016 Jul; 131():51-61. PubMed ID: 27265048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal robust control of drug delivery in cancer chemotherapy: a comparison between three control approaches.
    Moradi H; Vossoughi G; Salarieh H
    Comput Methods Programs Biomed; 2013 Oct; 112(1):69-83. PubMed ID: 23891423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis.
    Ledzewicz U; Schättler H
    J Theor Biol; 2008 May; 252(2):295-312. PubMed ID: 18371982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model.
    Barbolosi D; Iliadis A
    Comput Biol Med; 2001 May; 31(3):157-72. PubMed ID: 11173054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints.
    Mukherjee A; Majumder D
    Biosystems; 2008 Jan; 91(1):108-16. PubMed ID: 17889991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.